Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS
Launched by SHIRAZ UNIVERSITY OF MEDICAL SCIENCES · Feb 23, 2016
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
Polycystic ovary syndrome (PCOS) is estimated to affect up to10% of women of reproductive age, making it one of the most common endocrine disorders in this population. PCOS is associated with a broad range of adverse sequel, including hypertension, dyslipidemia, insulin resistance, hyperandrogenaemia, gestational and type 2 diabetes,which ultimately increase the cardiovascular morbidity in these patients. Also PCOS is increasingly recognized as a component of the metabolic syndrome. Management depends on symptoms or the source of androgen excess. Several treatment options are available, whi...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Age 18-35 years
- * Diagnosis of Polycystic Ovary Syndrome (PCOS) according to Rotterdam criteria 2003 (two out of three required):
- • 1. Oligomenorrhea or anovulation
- • 2. Clinical and/or biochemical signs of hyperandrogenism
- • 3. Polycystic ovaries (by ultrasound)
- Exclusion Criteria:
- • Smoking
- • Pregnancy
- • Diabetes mellitus
- • Renal failure (serum creatinine \>1.5)
- • Congenital adrenal hyperplasia
- • Hyper or hypothyroidism
- • Sex hormone therapy or antiandrogen therapy during the last three months
- • Unexplained serum alanin aminotransferase (ALT) elevation more than 2.5 times above normal range
- • Any systemic or febrile illnesses
- • Use of glucocorticoid or anti-inflammatory drugs during the last three months
- • Androgen secreting tumor
- • Malignancy
About Shiraz University Of Medical Sciences
Shiraz University of Medical Sciences (SUMS) is a leading academic institution in Iran dedicated to advancing healthcare through innovative research and education. As a prominent clinical trial sponsor, SUMS plays a pivotal role in conducting rigorous clinical studies aimed at improving medical practices and patient outcomes. The university is committed to fostering collaboration among healthcare professionals, researchers, and industry partners to translate scientific discoveries into effective therapies. With a focus on ethical standards and regulatory compliance, SUMS strives to contribute to the global body of medical knowledge while enhancing the quality of care within the community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shiraz, Fars, Iran, Islamic Republic Of
Patients applied
Trial Officials
Mesbah Shams, MD
Principal Investigator
Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences
Gholamhossein R Omrani, MD
Study Chair
Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials